by Truveta staff | May 30, 2025 | Research, Research Insights
Authors: Wilson Lau, PhD ⊕Truveta, Inc, Bellevue, WA,, Youngwon Kim, PhD ⊕Truveta, Inc, Bellevue, WA, Sravanthi Paras, MD ⊕Swedish Medical Center, Seattle, WA, Md Enamul Haque, PhD ⊕Truveta, Inc, Bellevue, WA,, Sara Daraei, PhD ⊕Truveta, Inc, Bellevue, WA, Rajesh Rao,...
by Truveta Research | May 30, 2025 | Research, Research Insights
Authors: Patricia J. Rodriguez, PhD, MPH ⊕Truveta, Inc, Bellevue, WA Duy Do, PhD ⊕Truveta, Inc, Bellevue, WA, Brianna M. Goodwin Cartwright, MS ⊕Truveta, Inc, Bellevue, WA, Jennifer Liang, MD ⊕Truveta, Inc, Bellevue, WA, Keenan Robbins, MBBS ⊕Washington University...
by Truveta staff | May 29, 2025 | Research
Each year, more than 34,000 men in the U.S. die from prostate cancer. While early-stage disease is often highly treatable, outcomes still vary widely — especially by race, income, and geography. Catching the disease early can save lives, but real-world data on...
by Truveta staff | May 21, 2025 | Research
A recent analysis using Truveta Data reveals that patients undergoing high-risk, non-emergency heart procedures (percutaneous coronary intervention, or PCI) with support from the Impella heart pump had better outcomes than those supported with an intra-aortic balloon...
by Truveta Research | May 16, 2025 | Research, Research Insights
Among children in Texas receiving a first measles vaccine prior to two years of life: In March and April 2025, 20.1% of all first measles vaccines were administered to children early (6-11 months). This is 11.5-fold higher than in 2019, when there were international...
by Truveta staff | May 15, 2025 | Research
Cancer is one of the most heavily funded areas of medical research. And yet, with thousands of therapies in development and billions of dollars spent each year, many foundational questions persist: Why do patients stop treatment? How do outcomes vary across...
